Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma

Multiple myeloma (MM) remains an incurable plasma cells malignancy because of its complex genetic heterogeneity and high relapse rate post immunotherapy. The encouraging results of chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen (BCMA) immunotherapy clinical trials have...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Tiantian, Shi, Jing, Liu, Huasheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423312/
https://www.ncbi.nlm.nih.gov/pubmed/30693373
http://dx.doi.org/10.1007/s00277-018-03592-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423312/
https://www.ncbi.nlm.nih.gov/pubmed/30693373
http://dx.doi.org/10.1007/s00277-018-03592-9

Ejemplares similares